U.S. Household Products Stock News

NYSE:PWR
NYSE:PWRConstruction

Assessing Quanta Services (PWR) Valuation After Strong Recent Share Price Momentum

Context for Quanta Services (PWR) after recent share moves Quanta Services (PWR) has attracted fresh attention after recent share price moves, with the stock showing a 19.3% return over the past month and 24.1% over the past 3 months. See our latest analysis for Quanta Services. While the latest share price of $566.0 comes after a small 1-day and 7-day pullback, the 1-month share price return of 19.3% and year-to-date share price return of 28.7%, together with a very strong 1-year total...
NYSE:OKLO
NYSE:OKLOElectric Utilities

Meta Prepayment Puts Spotlight On Oklo’s Long Term SMR Potential

Oklo (NYSE:OKLO) has signed a funding and power prepayment agreement with Meta Platforms tied to a future nuclear plant in Ohio. Meta has agreed to prepay for electricity from Oklo’s planned small modular reactor, providing capital before the plant begins commercial operations. The deal links Oklo’s SMR project to expected data center power needs, with the Ohio facility still several years from coming online. Oklo focuses on small modular reactors that aim to supply carbon free, always on...
NasdaqGM:CERS
NasdaqGM:CERSMedical Equipment

Cerus (CERS) Revenue Growth Outpaces Market And Reinforces Bullish Margin Recovery Narrative

Cerus (CERS) has just closed out FY 2025 with Q4 revenue of US$57.8 million and a basic EPS loss of US$0.01, while trailing 12 month figures sit at US$206.1 million in revenue and a basic EPS loss of US$0.08. Over recent quarters the company has seen revenue move from US$50.8 million in Q4 2024 to US$43.2 million in Q1 2025, then to US$52.4 million in Q2, US$52.7 million in Q3 and US$57.8 million in Q4, with basic EPS losses ranging between US$0.00 and US$0.04 per share across the same...
NasdaqGS:NFBK
NasdaqGS:NFBKBanks

Northfield Bancorp (NFBK) One Off US$41m Loss Reshapes Earnings Narratives For FY 2025

Northfield Bancorp FY 2025 Earnings: One Off Loss Knocks Back Full Year Picture Northfield Bancorp (NFBK) closed out FY 2025 with Q4 total revenue of US$39.7 million and a basic EPS loss of US$0.69, capping off a trailing 12 month net income of US$0.8 million and EPS of roughly US$0.02 that reflects the impact of a large one off charge. Over the past few quarters, revenue has moved from US$29.3 million in Q3 FY 2024 to US$39.7 million in Q4 FY 2025, while quarterly EPS has swung from US$0.28...
NYSE:PRM
NYSE:PRMChemicals

Why Perimeter Solutions (PRM) Is Down 7.7% After Profitability Plunges Despite Higher 2025 Sales – And What's Next

Perimeter Solutions, Inc. reported past fourth-quarter 2025 results showing sales rising to US$102.75 million from US$86.23 million a year earlier, but swinging from net income of US$144.17 million to a net loss of US$140.23 million. For 2025 as a whole, sales increased to US$652.86 million from US$560.97 million, yet net loss widened sharply to US$206.37 million, highlighting pressure on profitability even as the company expanded and integrated acquisitions. We’ll now examine how the...
NasdaqGS:TSCO
NasdaqGS:TSCOSpecialty Retail

A Look At Tractor Supply (TSCO) Valuation After Earnings Miss Dividend Hike And Expansion Plans

Earnings miss, margin pressure and higher dividend put Tractor Supply in focus Tractor Supply (TSCO) has drawn investor attention after reporting fourth quarter earnings and revenue below analyst forecasts, along with declining operating income and ongoing margin pressure. At the same time, the retailer raised its annual dividend by 4.3% and outlined plans to open 100 new stores, pairing short term challenges with longer term expansion goals. See our latest analysis for Tractor Supply. The...
NasdaqCM:NBBK
NasdaqCM:NBBKBanks

NB Bancorp (NBBK) Margin Surge Reinforces Bullish Earnings Narrative Despite Valuation Debate

NB Bancorp's FY 2025 Earnings Snapshot NB Bancorp (NBBK) has just closed out FY 2025 with fourth quarter total revenue of US$64.2 million and basic EPS of US$0.19, alongside quarterly net income of US$7.7 million. Over the past year, the bank has seen total revenue move from US$44.9 million in Q4 FY 2024 to US$64.2 million in Q4 FY 2025, while quarterly EPS shifted from US$0.40 to US$0.19. With trailing 12 month earnings growth reported at 350.6% and net profit margin running at 30.7% versus...
NasdaqCM:MARA
NasdaqCM:MARASoftware

MARA Holdings (MARA) Q4 US$1.7b Loss Reinforces Bearish Profitability Narratives

MARA Holdings (MARA) has just closed out FY 2025 with fourth quarter revenue of US$202.3 million and basic EPS of a US$4.70 loss, capping a volatile year in which quarterly revenue moved between US$213.9 million and US$252.4 million while EPS ranged from a US$1.55 loss to a US$2.29 profit. Over the same stretch, trailing twelve month revenue sat at US$907.1 million with a net loss of US$1.3b, setting up a results season where the story is less about top line scale and more about how much...
NasdaqGS:SRAD
NasdaqGS:SRADHospitality

Did FIFA’s Extended Integrity Deal and Buyback Just Shift Sportradar Group's (SRAD) Investment Narrative?

Sportradar Group AG recently reported full-year 2025 results showing sales of €1,289.97 million and net income of €100.32 million, alongside issuing 2026 revenue guidance, completing a €171 million share buyback, and recording a small goodwill and intangibles impairment. A key development was FIFA’s decision to extend and expand its AI-driven integrity services agreement with Sportradar through 2031, deepening the company’s role in safeguarding global football competitions across FIFA and...
NasdaqGS:MDGL
NasdaqGS:MDGLBiotechs

Madrigal Revenue Beats Highlight Rezdiffra Momentum And Investor Trade Offs

Madrigal Pharmaceuticals reported strong fourth quarter revenue, supported by demand for its new MASH therapy, Rezdiffra. Rezdiffra adoption is gaining traction in the commercial rollout, contributing to revenue that surpassed earlier expectations. Analysts have responded positively to the results, reflecting increased confidence in Madrigal’s commercial path for NasdaqGS:MDGL. Madrigal Pharmaceuticals, trading as NasdaqGS:MDGL, is drawing fresh attention after upbeat fourth quarter results...
NasdaqGS:LPLA
NasdaqGS:LPLACapital Markets

Should LPL’s Simplicity Alliance and Mixed Quarter Results Prompt Strategy Rethink From LPLA Investors?

LPL Financial Holdings and Simplicity Group previously announced a partnership under which, from May 1, 2026, Simplicity will become LPL’s preferred Brokerage General Agency, integrating LPL’s internal insurance unit and expanding advisors’ access to advanced insurance technology, planning support, and protection solutions. At the same time, LPL’s strong but expectation-missing quarterly results, evolving regulatory backdrop, and continued advisor recruiting underscore how business execution...
NasdaqGS:SATS
NasdaqGS:SATSMedia

EchoStar (SATS) Valuation Check As Wider Losses And SpaceX Spectrum Deal Mark A Turning Point

EchoStar (SATS) just posted full year 2025 results that combined a wider net loss with revenue slightly ahead of expectations, as heavy non cash impairments and restructuring costs hit the bottom line. See our latest analysis for EchoStar. Despite the heavier full year loss, EchoStar’s shares have been volatile rather than weak, with a 57.91% 90 day share price return and a very large 1 year total shareholder return. This reflects how investors have reacted to the planned spectrum sale to...
NYSEAM:IE
NYSEAM:IEMetals and Mining

How Investors May Respond To Ivanhoe Electric (IE) Revenue Uptick And Narrower 2025 Net Loss

Ivanhoe Electric Inc. has reported its full-year 2025 results, with sales rising to US$3.24 million from US$2.90 million and the net loss narrowing to US$105.87 million from US$128.62 million, compared with 2024. The reduction in basic loss per share from continuing operations, to US$0.79 from US$1.07, points to improving cost and earnings efficiency even as the business remains loss-making. Next, we will examine how Ivanhoe Electric’s improved revenue and narrower net loss shape the...
NasdaqGS:MRCY
NasdaqGS:MRCYAerospace & Defense

How Investors May Respond To Mercury Systems (MRCY) Amid Rising Focus On West Asia Defense Tensions

In recent days, Mercury Systems, a U.S.-based aerospace and defense technology company, saw increased investor attention as escalating tensions in West Asia drew focus to defense suppliers supporting advanced military capabilities. This development underscores how shifts in regional security risk can quickly spotlight companies providing embedded processing, electronic warfare, and sensor technologies that underpin modern defense systems. We’ll now examine how this heightened focus on...
NYSE:VOYA
NYSE:VOYADiversified Financial

Is Voya Financial (VOYA) Pricing Look Attractive After Recent Share Price Weakness?

If you are wondering whether Voya Financial's current share price reflects its true worth, this article will walk through the key numbers that matter for valuation. The stock last closed at US$67.61, with returns of 3.0% decline over 7 days, 11.8% decline over 30 days, 10.6% decline year to date, 0.2% decline over 1 year, 1.9% decline over 3 years, and 16.9% gain over 5 years, which gives you a mixed picture of recent and longer term performance. This piece was prompted to provide ongoing...
NasdaqGS:TCBI
NasdaqGS:TCBIBanks

Assessing Texas Capital Bancshares (TCBI) Valuation After Institutional Buying And $400m Debt Offering

Texas Capital Bancshares (TCBI) is back on investors’ radar after JPMorgan Chase & Co. and Quantbot Technologies LP increased their stakes. This comes alongside the bank’s completion of a $400 million fixed income offering. See our latest analysis for Texas Capital Bancshares. Despite some recent softness, with a 1 month share price return showing a 5.57% decline from a last close of US$95.53, Texas Capital Bancshares still carries a 1 year total shareholder return of 27.85%. This points to...
NasdaqGS:ADPT
NasdaqGS:ADPTLife Sciences

A Look At Adaptive Biotechnologies (ADPT) Valuation As CEO Updates MRD Growth And Profitability Outlook

Adaptive Biotechnologies (ADPT) shares are back in focus after CEO Chad Robins outlined fresh expectations for MRD testing volumes and profitability, updating investors on growth initiatives and margin targets for the coming years. See our latest analysis for Adaptive Biotechnologies. At a share price of US$16.08, Adaptive Biotechnologies has seen a 13.1% 30 day share price decline and a 6.1% 90 day share price decline. However, its 1 year total shareholder return of 98% and 3 year total...
NYSE:BRCC
NYSE:BRCCFood

Black Rifle Coffee (BRCC) Loss Reinforces Concerns Over Cash Runway Despite Revenue Near US$400 Million

BRC (BRCC) has wrapped up FY 2025 with Q4 revenue of US$112.7 million, alongside a basic EPS loss of US$0.03 and a net income loss of US$3.2 million, setting a clear snapshot of where the business stands today. The company has seen quarterly revenue move from US$89.9 million in Q1 2025 to US$112.7 million in Q4 2025, while basic EPS has ranged from a loss of US$0.07 in Q2 2025 to a smaller loss of US$0.00 in Q3 2025. This gives investors a fuller view of how the top line and per share results...
NasdaqGS:ICFI
NasdaqGS:ICFIProfessional Services

A Look At ICF International (ICFI) Valuation After Earnings And Revenue Miss On Federal Sector Weakness

ICF International stock: earnings miss, federal headwinds and a mixed near-term picture ICF International (ICFI) shares are back in focus after fourth quarter 2025 results came in below consensus on both earnings and revenue, as ongoing federal sector headwinds outweighed strength in commercial and non federal work. See our latest analysis for ICF International. The earnings miss and softer federal revenue backdrop appear to be weighing on sentiment. A 16.84% 1 month share price return...
NYSE:ED
NYSE:EDIntegrated Utilities

A Look At Consolidated Edison’s Valuation After Its Recent Follow On Equity Offering

Why Consolidated Edison raised fresh equity Consolidated Edison (ED) has just completed a follow on equity offering, issuing 7,000,000 new common shares for total proceeds of about $775.67 million at a price of $110.81 per share. See our latest analysis for Consolidated Edison. At a share price of $112.36, Consolidated Edison has recently recorded a 5.37% 1 month share price return and a 16.50% 3 month share price return, while its 5 year total shareholder return of 92.28% reflects a strong...
NYSE:HUBB
NYSE:HUBBElectrical

Assessing Hubbell (HUBB) Valuation After Recent Share Price Pullback And Conflicting Fair Value Signals

Why Hubbell (HUBB) Is On Investors’ Radar Today Hubbell (HUBB) is drawing attention after recent share price moves, with the stock showing mixed short term returns alongside stronger performance over the past 3 years and 5 years. See our latest analysis for Hubbell. At a latest share price of $488.49, Hubbell has pulled back with a 1-day share price return of a 5.51% decline and a 7-day share price return of a 7.26% decline, while its 1-year total shareholder return of 40.58% and 5-year total...
NYSE:SEMR
NYSE:SEMRSoftware

Semrush Holdings (SEMR) Returns To EPS Loss In Q4 FY 2025 Challenging Bullish Margin Story

Semrush Holdings (SEMR) just posted its FY 2025 numbers with Q4 revenue of US$117.7 million and a basic EPS loss of US$0.07, alongside a full year trailing revenue line of US$443.6 million and a trailing basic EPS loss of US$0.13. Over recent periods the company has seen quarterly revenue move from US$97.4 million in Q3 FY 2024 to US$117.7 million in Q4 FY 2025. Basic EPS has shifted from a profit of US$0.02 in Q4 FY 2024 to a loss of US$0.07 in Q4 FY 2025, which highlights a situation where...
NasdaqGS:BMRN
NasdaqGS:BMRNBiotechs

BioMarin (BMRN) Is Down 6.5% After PALYNZIQ Pediatric Label Expansion Approval - Has The Bull Case Changed?

In late February 2026, BioMarin Pharmaceutical received U.S. FDA approval for a supplemental Biologics License Application expanding PALYNZIQ’s use to pediatric phenylketonuria patients aged 12 and older, following Phase 3 PEGASUS data and under a REMS program due to immune-mediated safety risks including anaphylaxis. This label expansion meaningfully broadens PALYNZIQ’s treated population, underscoring BioMarin’s ability to convert late-stage rare disease programs into commercial assets...
NasdaqGS:REAL
NasdaqGS:REALSpecialty Retail

RealReal Reopens San Francisco Flagship As Brand And Valuation Questions Grow

The RealReal (NasdaqGS:REAL) has reopened its reimagined San Francisco flagship store. The refreshed location expands physical retail services and emphasizes community focused offerings. The move highlights the company’s continued connection to its founding city and support for the local luxury shopping corridor. The RealReal, a luxury resale platform, is putting fresh weight behind brick and mortar with its updated San Francisco flagship. For a business built around authenticated...